MaxiVAX Crafts New Approach To Cancer Vaccines

26 Nov 2014

• By John Davis

The Swiss biotech is advancing its novel cancer vaccine strategy into the clinic, using encapsulated cells releasing GM-CSF to boost the immune response to killed cancer cells, following analysis of why some other approaches to cancer vaccines have not been particularly successful.

The Geneva-based biotech MaxiVAX SA is aiming to develop a new approach to administering therapeutic cancer vaccines and boosting their effects that builds on lessons learnt from more than 20 years of disappointing results by other researchers in this field.

“Twenty years ago we thought antigenic tumor peptides were the answer, the magic bullet, but it appears researchers are still...